Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials

BACKGROUND: The majority of clinical trials of first-line systemic treatments for hepatocellular carcinoma (HCC) used placebo or sorafenib as comparators, and there are limited data providing a cross comparison of treatments in this setting, especially for newly-approved immune checkpoint inhibitor...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:World J Gastroenterol
Main Authors: Han, Yue, Zhi, Wei-Hua, Xu, Fei, Zhang, Chen-Bo, Huang, Xiao-Qian, Luo, Jian-Feng
Format: Artigo
Jezik:Inglês
Izdano: Baishideng Publishing Group Inc 2021
Teme:
Meta-Analysis
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8130040/
https://ncbi.nlm.nih.gov/pubmed/34040331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v27.i19.2415
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki